Literature DB >> 12003681

Cannabis and psychosis.

Louisa Degenhardt1, Wayne Hall.   

Abstract

There has been considerable debate about the reasons for the association observed between cannabis use and psychosis in both clinical and general population samples. Among the hypotheses proposed to explain the association are the following: 1) common factors explain the co-occurrence; 2 cannabis causes psychosis that would not have occurred in the absence of cannabis use; 3) cannabis precipitates psychosis among persons who were vulnerable to developing the disorders; 4) cannabis use worsens or prolongs psychosis among those who have already developed the disorder; and 5) that persons with psychosis are more likely to become regular or problematic cannabis users than persons without psychosis. This article evaluates the evidence on each of these hypotheses, including recent research on the role of the cannabinoid receptor system in schizophrenia. The evidence suggests that common factors do not explain the comorbidity between cannabis use and psychosis, and it is unlikely that cannabis use causes psychosis among persons who would otherwise not have developed the disorder. The evidence is more consistent with the hypotheses that cannabis use may precipitate psychosis among vulnerable individuals, increase the risk of relapse among those who have already developed the disorder, and may be more likely to lead to dependence in persons with schizophrenia.

Entities:  

Mesh:

Year:  2002        PMID: 12003681     DOI: 10.1007/s11920-002-0026-5

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  52 in total

1.  The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being.

Authors:  L Degenhardt; W Hall
Journal:  Psychol Med       Date:  2001-05       Impact factor: 7.723

2.  Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study.

Authors:  A Jablensky; N Sartorius; G Ernberg; M Anker; A Korten; J E Cooper; R Day; A Bertelsen
Journal:  Psychol Med Monogr Suppl       Date:  1992

3.  Cannabis use and psychosis.

Authors:  W Hall
Journal:  Drug Alcohol Rev       Date:  1998-12

4.  Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function.

Authors:  J M Cleghorn; R D Kaplan; B Szechtman; H Szechtman; G M Brown; S Franco
Journal:  J Clin Psychiatry       Date:  1991-01       Impact factor: 4.384

Review 5.  How does drug and alcohol misuse develop among people with psychotic illness? A literature review.

Authors:  P Phillips; S Johnson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2001-06       Impact factor: 4.328

6.  Methylphenidate, dextroamphetamine, and levamfetamine. Effects on schizophrenic symptoms.

Authors:  D S Janowsky; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1976-03

7.  Cannabis consumption as a prognostic factor in schizophrenia.

Authors:  M J Martinez-Arevalo; A Calcedo-Ordoñez; J R Varo-Prieto
Journal:  Br J Psychiatry       Date:  1994-05       Impact factor: 9.319

8.  Correlates of patterns of substance abuse among patients with schizophrenia.

Authors:  B J Cuffel; K A Heithoff; W Lawson
Journal:  Hosp Community Psychiatry       Date:  1993-03

9.  Cannabis and acute psychosis.

Authors:  P K McGuire; P Jones; I Harvey; P Bebbington; B Toone; S Lewis; R M Murray
Journal:  Schizophr Res       Date:  1994-09       Impact factor: 4.939

10.  Alcohol use and abuse in schizophrenia. A prospective community study.

Authors:  R E Drake; F C Osher; M A Wallach
Journal:  J Nerv Ment Dis       Date:  1989-07       Impact factor: 2.254

View more
  10 in total

1.  Two-part random effects growth modeling to identify risks associated with alcohol and cannabis initiation, initial average use and changes in drug consumption in a sample of adult, male twins.

Authors:  Nathan A Gillespie; Gitta H Lubke; Charles O Gardner; Michael C Neale; Kenneth S Kendler
Journal:  Drug Alcohol Depend       Date:  2011-12-15       Impact factor: 4.492

2.  Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications.

Authors:  Giorgio Marchese; Paola Casti; Stefania Ruiu; PierLuigi Saba; Angela Sanna; GianLuca Casu; Luca Pani
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

Review 3.  Cannabis controversies: how genetics can inform the study of comorbidity.

Authors:  Arpana Agrawal; Michael T Lynskey
Journal:  Addiction       Date:  2014-01-19       Impact factor: 6.526

4.  The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats.

Authors:  Marco Bortolato; Gian Nicola Aru; Roberto Frau; Marco Orrù; Grant Christopher Luckey; Gianluca Boi; Gian Luigi Gessa
Journal:  Psychopharmacology (Berl)       Date:  2004-07-28       Impact factor: 4.530

Review 5.  Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.

Authors:  William G Notcutt
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

6.  No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia.

Authors:  Chao Deng; Mei Han; Xu-Feng Huang
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

7.  Comorbidity between hypomania and substance use disorders.

Authors:  Elizabeth K Do; Briana Mezuk
Journal:  J Affect Disord       Date:  2013-06-02       Impact factor: 4.839

8.  Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia.

Authors:  Amy B Adolfo; Christopher G AhnAllen; Jennifer W Tidey
Journal:  Schizophr Res       Date:  2008-11-08       Impact factor: 4.939

9.  Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol.

Authors:  A A Boucher; J C Arnold; L Duffy; P R Schofield; J Micheau; T Karl
Journal:  Psychopharmacology (Berl)       Date:  2007-02-28       Impact factor: 4.415

Review 10.  Long-term consequences of adolescent cannabinoid exposure in adult psychopathology.

Authors:  Justine Renard; Marie-Odile Krebs; Gwenaëlle Le Pen; Thérèse M Jay
Journal:  Front Neurosci       Date:  2014-11-10       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.